Question 31

Prescribing two different beta-blockers for hypertension is an example of therapeutic duplication.

Therapeutic duplication occurs when a patient is prescribed multiple medications that serve the same therapeutic purpose, which can increase the risk of adverse effects without additional benefit. In this case, prescribing two different beta-blockers for hypertension exemplifies this concept.

A) Prescribing ibuprofen and acetaminophen together

This option is incorrect because ibuprofen and acetaminophen act through different mechanisms and can be safely used together for pain relief or fever reduction. Their combined use does not constitute therapeutic duplication, as they target similar symptoms but are distinct medications.

B) Prescribing two different statins for cholesterol

This option is also incorrect because using two different statins simultaneously is not a standard practice and can lead to increased side effects without enhanced therapeutic benefit. However, it does not fit the definition of therapeutic duplication in the context of standard care, as statins are generally not used together.

C) Prescribing two different beta-blockers for hypertension

This option is correct because beta-blockers are primarily used to manage hypertension, and prescribing two different beta-blockers would lead to therapeutic duplication. This practice could increase the risk of side effects without providing additional efficacy, making it a clear example of therapeutic duplication.

D) Prescribing two different ACE inhibitors for heart failure

This option is incorrect because using two different ACE inhibitors is generally not recommended and does not provide added benefit. It falls under the same concern as option B, where the potential for increased side effects outweighs any therapeutic advantage, yet it is not a typical example of therapeutic duplication.

Conclusion

Prescribing two different beta-blockers for hypertension clearly exemplifies therapeutic duplication, as it involves the use of multiple medications that share the same therapeutic intent, potentially leading to adverse effects. The other options do not meet the criteria for therapeutic duplication in the same way, either representing safe combinations or practices that are not standard.